What Aimovig (erenumab) trials were done, and what were they designed to show?
Aimovig is a preventive treatment for migraine. The main clinical trials were built to test whether monthly erenumab injections reduce migraine frequency compared with placebo, and whether patients can stay on treatment with manageable side effects. The program also looked at patient subgroups such as those with episodic versus chronic migraine and people who had failed other migraine preventives.
How did the key Aimovig studies compare episodic vs chronic migraine?
The trial program included studies in both:
- Episodic migraine (fewer headache days per month), and
- Chronic migraine (headache on at least 15 days per month).
In both settings, the central measure was typically change from baseline in monthly migraine days, plus safety and tolerability during treatment.
What counts as success in Aimovig migraine-prevention trials?
Across Aimovig’s pivotal studies, success generally meant:
- A statistically significant reduction in monthly migraine days versus placebo, and
- A meaningful proportion of patients achieving larger reductions (commonly described as 50% response in migraine-day reduction), along with an acceptable safety profile.
What were the main side effects reported in Aimovig trials?
In published study results, side effects commonly tracked in migraine-prevention trials included injection-site reactions and constipation. Because Aimovig blocks the CGRP pathway, the safety findings also focused on effects seen in that class.
How long were Aimovig trials, and what happened during longer follow-up?
Aimovig’s clinical development included both controlled studies and longer follow-up extensions to evaluate whether migraine reduction persisted over time and whether new safety signals emerged with continued dosing.
Are there any “Aimovig trial” options that patients can still join?
If you mean current clinical trials, eligibility depends on geography, diagnosis (episodic vs chronic migraine), prior preventive treatments, and prior exposure to CGRP-targeting therapies. Trial listings are updated frequently, so the most reliable next step is to check current postings through clinical-trial registries and discuss options with a clinician.
Where can I find the most up-to-date Aimovig trial and patent/market timeline context?
For a combined view of the product’s status (including related patent or market exclusivity context), DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/p/drug/erenumab/ (search within that page for Aimovig-related details).
Quick clarification (so I can target the exact trial you mean)
When you say “Aimovig trial,” do you want:
1) the specific pivotal trial names (and their results),
2) side effects from the trials,
3) how to find or join current trials,
4) or the patent/exclusivity timeline around Aimovig?
If you tell me which one, I’ll narrow to the exact study details.